Crossmark

Insulin therapy for type 2 diabetes – are we there yet? The d-Nav® story

Crossref DOI link: https://doi.org/10.1186/s40842-018-0056-5

Published Online: 2018-04-10

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hodish, I.
Funding

Funding for this research was provided by:

Hygieia Inc.
License Information

Text and Data Mining valid from 2018-04-10
More Information

Article History

Received: 3 November 2017

Accepted: 20 February 2018

First Online: 10 April 2018

Ethics approval and consent to participate

: Not applicable.

: The three index patients have already signed the forms.

: Israel Hodish is a co-founder of Hygieia Inc. and own stocks of the same. He is a co-inventor of patents related to the presented technology.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.